2024
Estimated Health and Economic Outcomes of Racial and Ethnic Tuberculosis Disparities in US-Born Persons
Swartwood N, Li Y, Regan M, Marks S, Barham T, Asay G, Cohen T, Hill A, Horsburgh C, Khan A, McCree D, Myles R, Salomon J, Self J, Menzies N. Estimated Health and Economic Outcomes of Racial and Ethnic Tuberculosis Disparities in US-Born Persons. JAMA Network Open 2024, 7: e2431988. PMID: 39254977, PMCID: PMC11388029, DOI: 10.1001/jamanetworkopen.2024.31988.Peer-Reviewed Original ResearchConceptsUS-born personsEthnic disparitiesCase-fatality rateTB deathsTB casesTB incidenceSex-adjusted incidenceNational TB surveillance dataTB surveillance dataQuality-adjusted life yearsDistrict of ColumbiaTB disparitiesHealth outcomesEconomic outcomesFuture healthOutcome of TBUS-bornTB outcomesEstimate healthLife yearsSocietal costsTB burdenSocietal perspectiveGeneralized additive regression modelsGoal attainmentCost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study
van Lieshout Titan A, Klaassen F, Pelissari D, de Barros Silva J, Alves K, Alves L, Sanchez M, Bartholomay P, Johansen F, Croda J, Andrews J, Castro M, Cohen T, Vuik C, Menzies N. Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study. The Lancet Global Health 2024, 12: e1446-e1455. PMID: 39151980, PMCID: PMC11339731, DOI: 10.1016/s2214-109x(24)00221-3.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsTuberculosis preventive treatmentTuberculosis deathsHealth impactsImpact of screeningIntervention cost-effectivenessInfection screeningCost-effectiveNational Institutes of HealthHealth outcomesHealth gainsInstitutes of HealthQuantify health effectsTuberculosis casesCost-effectiveness ratioTreatment of Mycobacterium tuberculosis infectionPotential health impactsLife yearsGreater health benefitsTuberculosis preventionTarget populationMonths of isoniazidMarkov modelling studiesHealth statesHealth
2023
Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis
Menzies N, Allwood B, Dean A, Dodd P, Houben R, James L, Knight G, Meghji J, Nguyen L, Rachow A, Schumacher S, Mirzayev F, Cohen T. Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis. Nature Communications 2023, 14: 6182. PMID: 37794037, PMCID: PMC10550952, DOI: 10.1038/s41467-023-41937-9.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsRifampicin-resistant tuberculosisRR-TBGlobal burdenSubstantial short-term morbidityRifampicin-susceptible tuberculosisShort-term morbidityOverall disease burdenLong-term health impactsPost-treatment careTB survivorsDisease burdenTreatment outcomesTuberculosis survivorsCase detectionLife yearsRifampicin resistanceTuberculosisHealth impactsBurdenHealth expenditureDiseaseSurvivorsMathematical modeling analysisFormer Soviet Union countriesTabby2: a user-friendly web tool for forecasting state-level TB outcomes in the United States
Swartwood N, Testa C, Cohen T, Marks S, Hill A, Beeler Asay G, Cochran J, Cranston K, Randall L, Tibbs A, Horsburgh C, Salomon J, Menzies N. Tabby2: a user-friendly web tool for forecasting state-level TB outcomes in the United States. BMC Medicine 2023, 21: 331. PMID: 37649031, PMCID: PMC10469407, DOI: 10.1186/s12916-023-02785-y.Peer-Reviewed Original ResearchConceptsLatent tuberculosis infectionTB outcomesDistrict of ColumbiaTreatment of LTBIIncremental cost-effectiveness ratioTB incidence rateTuberculosis disease burdenQuality-adjusted life yearsCost-effectiveness ratioPublic health agenciesTB casesTB preventionTB incidenceTuberculosis infectionTB epidemiologyDisease burdenIncidence rateService utilizationAdditional interventionsIncidence projectionsLife yearsDemographic dataSocietal perspectiveHealth agenciesPrevention approaches
2021
The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease
Menzies NA, Shrestha S, Parriott A, Marks SM, Hill AN, Dowdy DW, Shete PB, Cohen T, Salomon JA. The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease. Epidemiology 2021, 33: 75-83. PMID: 34669631, PMCID: PMC8633045, DOI: 10.1097/ede.0000000000001418.Peer-Reviewed Original ResearchConceptsPositive predictive valueHigh positive predictive valueFuture tuberculosisLatent tuberculosis infection treatmentIncremental costHigher treatment initiationCompletion of treatmentInterferon-gamma releaseQuality-adjusted life yearsTransmission dynamic modelLTBI testingTreatment initiationTreatment acceptanceTuberculosis diseasePrevention servicesPredictive valueTreatment servicesLife yearsTuberculosisInfection treatmentSocietal perspectiveIGRATreatment volumeHealth improvementFuture progression